Endocrinology, Vol 109, 798-802, Copyright © 1981 by Endocrine Society

ARTICLES

Alpha-adrenergic stimulation by clonidine increases plasma concentrations of immunoreactive beta-endorphin in rats

DJ Pettibone and GP Mueller

Peripheral administration of the alpha-adrenergic agonist clonidine (0.5 mg/kg, sc) evoked a 2- to 3-fold rise (0.22 +/- 0.03 to 0.59 +/- 0.05 ng/ml) in plasma levels of beta-endorphin-like immunoreactivity (beta-END-LI) 15-30 min later in intact, but not hypophysectomized, rats. This rise in plasma beta-END-LI, which was dose dependent up to 0.5 mg/kg clonidine, appeared to be mediated by activation of alpha- adrenergic receptors, since pretreatment with the alpha-adrenergic antagonists yohimbine (1 mg/kg, ip), phentolamine (1, 3, or 10 mg/kg, kp), or phenoxybenzamine (2 and 10 mg/kg, ip) partially or fully blocked clonidine's effect. By contrast, the beta-adrenergic antagonist propranolol (1 and 5 mg/kg, ip) did not modify the clonidine-induced increased in plasma beta-END-LI. Given alone, the adrenergic blocking drugs were generally without effect on plasma levels of beta-END-LI. Clonidine appeared to be acting on the brain (or pituitary), since the intracerebroventricular injection of phenoxybenzamine (20 microgram) blocked the drug-induced rise in plasma beta-END-LI. These data suggest an alpha-adrenergic mechanism influences the release of pituitary beta- END in the rat.

This article has been cited by other articles:

				G. A. Tejwani and A. K. Rattan Antagonism of Antinociception Produced by Intrathecal Clonidine by Ketorolac in the Rat: The Role of the Opioid System Anesth. Analg., May 1, 2000; 90(5): 1152 - 1156. [Abstract] [Full Text] [PDF]